Please assess the completion status of the following clinical trial:

Trial Title: A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The subject is healthy.~* Body mass index less than 29.0 kg/m² , weight range of 55.0kg (females 50kg) to 95.0kg inclusive.~* They have a history of hayfever (repeated yearly episodes).~* They have a positive skin prick test for grass pollen at or within the 12 months preceding the screening visit.~* They have a positive radioallergosorbent test for grass pollen at or within the 12 months preceding the screening visit.~* non-smokers.~* They must have a baseline FEV1\>80% predicted and a baseline FEV1(maximum recorded value)/ forced vital capacity (FVC) (maximum recorded value)\>70%~* They are capable of giving informed consent~* They are available to complete all study measurements.~Exclusion Criteria:~* Pregnant or nursing females.~* Women of childbearing potential who are unwilling or unable to use an appropriate method of contraception.~* The subject has structural nasal abnormalities or nasal polyposis.~* Any respiratory disease other than mild stable asthma that is controlled with occasional use of as-needed short-acting beta-agonists and associated with normal lung function.~* The subject has a history of drug or other allergy that may contraindicate participation.~* The subject has participated in a study with a new molecular entity during the previous 4 months or in any clinical study in the previous 3 months~* The subject is concurrently participating in another clinical study and is exposed to an investigational or a non-investigational drug or device.~* The subject has a screening QTc value \>450msec, PR interval outside the range 120 to 240msec or an ECG that is not suitable for QT measurements.In addition subjects will be excluded if they have a history of atrial and ventricular arrhythmia.~* The subject has a supine blood pressure that is persistently higher than 140/90 millimetres of mercury (mmHg) at screening.~* The subject has donated a unit of blood (450mL) within the previous 3 months or intends to donate within 3 months of completing the study.~* The subject is currently taking regular (or a course of) medication whether prescribed or not, including steroids, vitamins, and herbal remedies (e.g. St. John's Wort). Paracetamol (\<2g/day) and occasional as needed use of short-acting beta agonists is permitted.~* Past or present disease which may affect study. outcome~* The subject regularly, or on average, drinks more than 4 units of alcohol per day - where 1 unit = ½ pint of beer (284mL), or 1 glass of wine (125mL), or 1 measure of spirit (25mL).~* The subject is at risk of non-compliance with the study procedures/restrictions.~* The subject has Hepatitis B, Hepatitis C, or HIV virus.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).